Platelet aggregation inhibitors

A method to detect the presence or absence of the peptide selected from the group consisting of:

• ______________________________________ PAI 80 Mpr-P-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:1) PAI 81 Mpr-G-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:2) PAI 82 Mpr-A-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:3) PAI 83 Mpr-Aib-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:4) PAI 84 Mpr-(N-Me-Arg)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:5) PAI 85 Mpr-(N-Me-Ser)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:6) PAI 86 Mpr-(D-Ala)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:7) PAI 87 Mpr-(.beta.-Ala)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:8) PAI 88 Mpr-(N-Me-Leu)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:9) PAI 89 Mpr-(N-Me-Ala)-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:10) PAI 90 Mpr-Sar-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:11) PAI 91 Mpr-V-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:12) PAI 92 Mpr-S-Har-G-D-W-P-C-NH.sub.2 (SEQ ID No:13) PAI 93 Mpr-Har-G-D-W-P-A-C-NH.sub.2 (SEQ ID No:14) PAI 94 Mpr-Har-G-D-W-P-(N-Me-Ala)-C-NH.sub.2 (SEQ ID No:15) PAI 95 Mpr-Har-G-D-W-P-G-C-NH.sub.2 (SEQ ID No:16) PAI 96 Mpr-Har-G-D-W-P-(D-Ala)-C-NH.sub.2 (SEQ ID No:17) PAI 97 Mpr-Har-G-D-W-P-P-C-NH.sub.2 (SEQ ID No:18) PAI 98 Mpr-Har-G-D-W-P-(Sar)-C-NH.sub.2 (SEQ ID No:19) PAI 99 Mpr-Har-G-D-W-P-(Aib)-C-NH.sub.2 (SEQ ID No:20) PAI 100 Mpr-A-(Har)-G-D-W-P-Pen-NH.sub.2 (SEQ ID No:21) PAI 101 Mpr-A-K-G-D-W-P-Pen-NH.sub.2 (SEQ ID No:22), and PAI 102 Mpr-D-(Har)-G-D-W-P-Pen-NH.sub.2 (SEQ ID No:23) ______________________________________
• which method comprises contacting a sample suspected of containing said peptide with an antibody specifically immunoreactive with said peptide under conditions wherein a complex is formed in the presence of said peptide, and detecting the presence or absence of said complex.